10月17日，东曜药业-B(01875)盘中下跌5.05%，截至13:00，报1.88元/股，成交801.62万元。
东曜药业股份有限公司主要业务是提供生物药，特别是抗体偶联药（ADC）的开发生产一站式CDMO解决方案，主力产品已经实现了20,000L的产能。公司拥有一体化的ADC研发平台以及符合GMP规范的大规模生物药商业化生产基地，专门支持多个上市产品的商业化生产，并提供降低转移成本及减少监管风险的一站式解决方案。
截至2024年中报，东曜药业-B营业总收入5.21亿元、净利润3155.9万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.